Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System(TM) for Type 1 Diabetes

Stock Information for Sernova Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sernova Corp.

Sernova Provides Positive Clinical and Platform Portfolio Update
Sernova Announces Management Developments
Sernova Provides Recap of 2023 Accomplishments and Anticipated 2024 Milestones
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System(TM) at the 2023 IPITA-IXA-CTRMS Joint Congress
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System(TM) for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress
Sernova Presents Compelling New Data on the Cell Pouch System(TM) as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.